Immunotherapy and chemotherapy for newly diagnosed high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (dinutuximab-beta plus chemotherapy) for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if adding this targeted therapy to standard chemo improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 1 and 30 years old when first diagnosed
- Must have a confirmed diagnosis of high-risk neuroblastoma (a childhood nerve-cell cancer)
- Must not have had any prior systemic treatment, or only the first round of induction chemotherapy
- Must have at least one visible tumor on a scan (MRI, CT, MIBG, or PET) within the last few weeks
- Must be generally healthy with good organ function (heart, kidneys, liver, lungs)
- Must be enrolled in a related standard care protocol and agree to long-term follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This study tests adding two medications (naxitamab and GM-CSF) to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma, a cancer of nerve cells. The goal is to help the body's immune system fight the cancer more effectively.
This Phase 3 study tests treatment strategies for children with high-risk neuroblastoma, aiming to improve how well the cancer responds and how long patients can stay in control. It compares different intensities and add-ons at key treatment steps depending on your child’s response and health.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new High-Risk Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.